Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition
Obicetrapib, a next-generation cholesteryl ester transfer protein (CETP) inhibitor, is emerging as a potent therapeutic option to address residual cardiovascular risk in patients not achieving optimal outcomes with existing lipid-lowering therapies, such as statins, ezetimibe and proprotein convertase subtilisin/kexin...